Literature DB >> 26292710

MLN4924 therapy as a novel approach in cancer treatment modalities.

Maryam Oladghaffari1, Jalil Pirayesh Islamian2,3, Behzad Baradaran3, Ali Shabestani Monfared1.   

Abstract

MLN4924 is an investigational and a newly discovered small molecule that is a potent and selective inhibitor of the NEDD8 (Neural precursor cell-Expressed Developmentally down-regulated 8) Activating Enzyme (NAE), a pivotal regulator of the Cullin Ring Ligases E3 (CRL), which has been implicated recently in DNA damage. MLN4924 effectively inhibits tumour cell growth by inducing all three common types of death, namely apoptosis, autophagy and senescence and it was also reported that the formation of capillary vessels was significantly suppressed by MLN4924.In this review, we are going to highlight the molecular mechanism of MLN4924 in cancer therapy and its pros and cons in cancer therapy.

Entities:  

Keywords:  Apoptosis; Cancer treatment; MLN4924; NEDD8 activating enzyme; UPS inhibitors (UPSI); Ubiquitin-proteasome system (UPS)

Mesh:

Substances:

Year:  2016        PMID: 26292710     DOI: 10.1179/1973947815Y.0000000066

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  12 in total

1.  Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.

Authors:  Jian-Ang Li; Chao Song; Yefei Rong; Tiantao Kuang; Dansong Wang; Xuefeng Xu; Jian Yuan; Kuntian Luo; Bo Qin; Somaira Nowsheen; Zhenkun Lou; Wenhui Lou
Journal:  Cell Cycle       Date:  2018-01-03       Impact factor: 4.534

2.  Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin.

Authors:  Shan Lin; Zhaoyang Shang; Shuo Li; Peng Gao; Yi Zhang; Shuaiheng Hou; Peng Qin; Ziming Dong; Tao Hu; Ping Chen
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

Review 3.  A patent review of the ubiquitin ligase system: 2015-2018.

Authors:  Xin Li; Ekinci Elmira; Sagar Rohondia; Jicang Wang; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2018-11-23       Impact factor: 6.674

4.  Cdk2 suppresses IL-23 expression and the onset of severe acute pancreatitis.

Authors:  Yanpeng Ma; Longlong Liu; Bin Li; Wenyao Wang; Tingting Zhao
Journal:  Immun Inflamm Dis       Date:  2022-06

5.  Targeted inhibition of the COP9 signalosome for treatment of cancer.

Authors:  Anita Schlierf; Eva Altmann; Jean Quancard; Anne B Jefferson; René Assenberg; Martin Renatus; Matthew Jones; Ulrich Hassiepen; Michael Schaefer; Michael Kiffe; Andreas Weiss; Christian Wiesmann; Richard Sedrani; Jörg Eder; Bruno Martoglio
Journal:  Nat Commun       Date:  2016-10-24       Impact factor: 14.919

6.  Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation.

Authors:  Nadezhda Tikhmyanova; Steve Tutton; Kayla A Martin; Fang Lu; Andrew V Kossenkov; Nicholas Paparoidamis; Shannon Kenney; Joseph M Salvino; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2017-07-17       Impact factor: 6.823

Review 7.  Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.

Authors:  Sang-Min Jang; Christophe E Redon; Mirit I Aladjem
Journal:  Front Mol Biosci       Date:  2018-03-13

Review 8.  Specific targeting of the deubiquitinase and E3 ligase families with engineered ubiquitin variants.

Authors:  Maryna Gorelik; Sachdev S Sidhu
Journal:  Bioeng Transl Med       Date:  2016-11-14

9.  TET1 inhibits cell proliferation by inducing RASSF5 expression.

Authors:  Bo-Tai Li; Chao Yu; Ying Xu; Sheng-Bing Liu; Heng-Yu Fan; Wei-Wei Pan
Journal:  Oncotarget       Date:  2017-09-23

10.  A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.

Authors:  Paige M Chorner; Roger A Moorehead
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.